Levorphanol

Levorphanol
Clinical data
Trade namesLevo-Dromoran
Other namesRo 1-5431
AHFS/Drugs.comMonograph
MedlinePlusa682020
Routes of
administration
Oral, intravenous, subcutaneous, intramuscular
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Bioavailability70% (oral); 100% (IV)
Protein binding40%
MetabolismHepatic
Elimination half-life11–16 hours
Identifiers
  • (1R,9R,10R)-17-Methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.912
Chemical and physical data
FormulaC17H23NO
Molar mass257.377 g·mol−1
3D model (JSmol)
  • CN1CC[C@]23CCCC[C@H]2[C@H]1Cc4c3cc(O)cc4
  • InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1 Y
  • Key:JAQUASYNZVUNQP-USXIJHARSA-N Y
 NY (what is this?)  (verify)

Levorphanol (brand name Levo-Dromoran) is an opioid medication used to treat moderate to severe pain. It is the levorotatory enantiomer of the compound racemorphan. Its dextrorotatory counterpart is dextrorphan.

It was first described in Germany in 1946. The drug has been in medical use in the United States since 1953.